Evaxion Biotech A/S

Evaxion takes important step to significantly strengthen our equity     We are in advanced discussions with the European Investment Bank (EIB) about conversion of €3.5 million out of our €7 million loan with EIB into an equity-type instrument. Such conversion is expected to increase our equity by $3.7 million immediately upon completion. As the conversion would significantly enhance our equity and capital structure, it is an important part of our plan on ensuring ongoing compliance with the Nasdaq listing requirements. An agreement is expected to be finalized and implemented in the first quarter of 2025. Read more in today’s press release: https://lnkd.in/dXdCsQEm

At Evaxion Biotech, our mission has always been clear: to harness the power of artificial intelligence to save and improve patients’ lives. Through our proprietary AI-Immunology™ platform, we are tackling the complex task of decoding the human immune system, which allows for more efficient vaccine antigen discovery and development. This cutting-edge platform enables us to develop personalized and precision vaccines that bring hope to those facing cancer, bacterial diseases, and viral infections. Today, we’re excited to announce an evolution in our digital presence:                           🌐 From now on, you can find us at www.evaxion.ai! This new domain reflects our unwavering commitment to innovation and reinforces the central role of AI in everything we do. It’s a small but meaningful step as we continue advancing our vision of transforming patient care. As we move into 2025, we’re ready to embrace a new chapter of innovation and impact 👊

Evaxion establishes new AI-derived precision cancer vaccine concept    Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patients.  Novel preclinical data confirming the effectiveness of the ERV-based precision vaccine is presented at ESMO Immuno-Oncology Congress in Geneva, Switzerland.    The precision vaccine has shown to induce strong T-cell responses and tumor growth inhibition in mice, thereby establishing preclinical Proof-of-Concept. The approach could allow for a broader use of cancer vaccines, also for patients not responding to conventional immunotherapies.    For more information, read our recent press release: https://lnkd.in/d5RyC_i9. To access the poster with the data presented at ESMO, follow this link: https://lnkd.in/dwvKPfmb.

Evaxion announces 2025 milestones reflecting continued strong strategy execution 🗓️   Having achieved almost all the milestones set for 2024, we announce the following year’s strategic milestones reflecting Evaxion’s high activity and strong external interest in potential partnerships around our AI-Immunology™ platform and pipeline assets.   Moving confidently towards 2025, our overriding priorities are execution upon our business development strategy, continuation of the ongoing EVX-01 phase 2 trial, the ongoing strengthening of our AI-Immunology™ platform and further advancement of our research activities.   All this is reflected in the 2025 milestones table, as seen below. For more information on this announcement, read our recent press release: https://lnkd.in/deQTS3K7

Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at next week’s ESMO Immuno-Oncology Congress!   Exploiting the unique capabilities of AI-Immunology™ to identify and select non-conventional ERV (endogenous retrovirus) tumor antigens shared across patients, Evaxion has developed a novel precision cancer vaccine concept that could potentially enable treatment of patients who are unresponsive to conventional cancer treatments.   The data supporting this novel concept stems from studies in human cells and mouse tumor models and will be presented at the ESMO Immuno-Oncology Congress, taking place in Geneva, Switzerland, from December 11-13, 2024.   ESMO - European Society for Medical Oncology represents more than 40,000 oncology professionals in 177 countries and is a reference for oncology education and information. Founded in 1975, ESMO seeks to erase boundaries in cancer care, whether between countries or specialties, and pursue its mission of advancing and improving the quality of prevention, diagnosis and treatment across oncology worldwide.   For more information, read our recent press release: https://lnkd.in/dCAYQtQm

🎄✨ ’Tis the season to be jolly! ✨🎄 At Evaxion, we’re not just about changing lives through innovation — we’re also about celebrating the moments that bring us together. This week, we gathered under the glow of our beautifully decorated Christmas tree to embrace the holiday spirit! With the sound of laughter from little ones running around, grownups getting creative with seasonal handcrafts, and the scent of festive treats in the air, our offices momentarily transformed into a cozy holiday wonderland. Moments like these remind us that it’s not just about the work we do — it’s about the people we share it with. From all of us at Evaxion, we wish you a holiday season filled with warmth, joy, and togetherness. ️🎅🎁

Evaxion at this year’s Synapse Life Science Career Fair in Copenhagen! Based on successful previous participations, we have once again joined the Synapse career fair to connect with students across the life science fields. This event is organized by Synapse DK - Life Science Connect, a student-driven non-profit organization in the Nordics which has previously hosted similar events with over 500 student participants (BSc, MSc, Ph.D., and recent graduates), indicating the booming interest among students for local companies within the life science sector. Yesterday, we had a series of engaging interactions that left us inspired and excited about the capabilities and motivation of the potential next generation of Evaxers. If you are one of the students with an interest in working or doing your thesis with us, remember to send an application to our open application platform: https://lnkd.in/dXZf9n6G

Strong advancements on Evaxion’s first AI-Immunology™ powered viral vaccine program, EVX-V1!   We are excited to announce notable advancements in our cytomegalovirus (#CMV) vaccine program, which began in December 2022. To combat the virus from multiple angles and develop a robust, next-generation vaccine, our AI-Immunology™ platform has identified novel antigens capable of effectively triggering targeted immune responses, including induction of both reactive B and T cells. This novel multi-target approach stands out from traditional methods focusing on a limited set of glycoproteins and is expected to enhance the efficacy of our future vaccine.   Furthermore, through innovative design efforts, we have successfully produced a proprietary prefusion glycoprotein B (gB) antigen capable of inducing a specific immune response comparable to that of the conventional gB antigen.   The data will be presented today at the @9th International Conference on Vaccines R&D in Boston, USA. We look forward to the successful advancement of this vaccine program to help tackle this widespread infection affecting more than half of the population with the potential to develop severe symptoms as well as severely affecting newborn babies. For more information, read our recent press release: https://lnkd.in/d_VKvy89

Evaxion is happy to announce its attendance at this year’s international conference on Vaccines Research & Development taking place on November 11-13 in Boston, MA. With esteemed speakers from various sectors, including academia, industry, and regulatory agencies, we look forward to engaging in interdisciplinary discussions within the field of vaccine research. If you’re attending the congress, we welcome you to join our Senior Project Manager in Infectious Diseases and Antigen Discovery, Gry Persson, for her presentation on how Evaxion’s AI-Immunology™ platform can help revolutionize the development of cytomegalovirus vaccine development. The presentation will take place on Tuesday, November 12, at 9:40 AM EST / 15:40 CET.   You can read more about the conference on our website, where you also find a list of all our upcoming events:

Last week, our CEO, Christian Kanstrup, featured in The Big Biz Show, where he shared the intriguing story of Evaxion and how the company, rooted in machine learning and advanced computational methods, emerged as one of the very few AI-first companies. Since the inception in 2008, Evaxion have developed a unique and strongly validated AI-Immunology™ platform that, as Christian explains it, positions us at the forefront of using AI to discover, design, and develop novel vaccine candidates for cancer and infectious diseases.    In the latter part of the interview, you will also hear more about our leading personalized peptide-based cancer vaccine, EVX-01, and how we target the unique tumor profile and immune characteristics of each patient with metastatic melanoma.